PBPK workflow for predicting clinical DDI risk of OATP1B1/3 inhibitors utilizing the CP-I biomarker: A case study with cyclosporine A

PBPK Conference 2026, Poster 23

Kanacher T, Pellowe M, Kovar C, Eriksson J, Wu J, Busse D, Gómez-Mantilla JD, Stopfer P, Ince I, Huang F